COMMUNIQUÉS West-GlobeNewswire

N.M. Judge Orders NMDOH to Designate Dispensary Locations
25/10/2018
State agency must designate Ultra Health’s outstanding and future stores per judge’s order BERNALILLO, N.M., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Chief Judge Louis P. McDonald of the Thirteenth Judicial District has [...]
Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
25/10/2018
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis -- -- Reveals Potential New Role for Chemokine Receptor 2 ( [...]
GUERBET : Revenue at September 30, 2018
25/10/2018
€614.3M at constant exchange rates, up 2.1% Villepinte, 25 October 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €581.4M for the [...]
GUERBET : Chiffre d'affaires au 30 septembre 2018
25/10/2018
614,3 M€ à taux de change constant (TCC) en progression de 2,1% Villepinte, le 25 octobre 2018 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, publie un [...]
Nova Leap Health Corp. Closes Second Tranche of Brokered and Non-Brokered Private Placements
25/10/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Oct. 25, 2018 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or “the Company”), a [...]
Undoing Aging 2019 Conference Seeks Abstracts for Poster Session
25/10/2018
MOUNTAIN VIEW, Calif. and BERLIN, Oct. 25, 2018 (GLOBE NEWSWIRE) -- The SENS Research Foundation and the Forever Healthy Foundation are seeking abstracts for the 2019 Undoing Aging Conference poster sessions. Undoing [...]
Certis Oncology Collaborates With Science Exchange to Offer On-Demand Access to its Orthotopic PDX Services
25/10/2018
SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Science Exchange, the leading marketplace for outsourced R&D, and Certis Oncology , a leading provider for preclinical mouse modeling and tumor banking services, [...]
Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia
25/10/2018
Valby, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Corporate Release Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia Lu AF35700 did not show statistical superiority versus [...]
Long-term incentive program (replacement of company announcement no. 17/2018)
25/10/2018
Company Announcement No. 18/2018 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 About Chr. [...]
Eko Collaborates with Mayo Clinic on a Machine Learning-Based Algorithm to Help Physicians Better Screen for Potentially Dangerous Heart Diseases
25/10/2018
Eko’s software and smart digital stethoscope combined with Mayo’s vast data and tech aims to help physicians with earlier detection of life-threatening conditions Berkeley, CA, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Eko , [...]
Phoenix Life Sciences International Announces Dr. Philip Blair as Diabetes Director of Medical Advisory Council
25/10/2018
DENVER, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Phoenix Life Sciences International Limited (OTCMarkets: MJMD) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Col. Philip Blair, [...]
XBiotech annonce le rejet du recours collectif sur les valeurs mobilières
25/10/2018
AUSTIN, Texas, 25 oct. 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui que l’Honorable juge Dustin M. Howell de la 459 e Cour de district du Comté de Travis a rendu sa décision dans une [...]
111, Inc. Establishes Strategic Partnerships with Mentholatum China and Zhongxin Pharmaceuticals
25/10/2018
SHANGHAI, China, Oct. 25, 2018 (GLOBE NEWSWIRE) -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced it has established strategic partnerships [...]
CrownBio Releases MuBase® 2.0, An Open Access Database of Immuno-Oncology Murine Models
25/10/2018
Updates enhance user experience, provide comprehensive characterization data, and add new models SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company [...]
Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting
25/10/2018
-- Additional data and analyses suggest that in the OV101 15 mg once-daily dose group, changes in sleep parameters and motor domains contributed to the statistically significant improvement in overall clinical global [...]
VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study
25/10/2018
PH10 demonstrated in Phase 2a study significant antidepressant effects without psychological side effects after only one week of administration SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- VistaGen [...]
Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for Attendees of the Advanced Cell Therapy Summit in Shanghai
25/10/2018
SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]
Tauriga Sciences Inc. Reaches Agreements to Retire the Remainder of its Outstanding Convertible Debt
25/10/2018
New York, Oct. 25, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. ( TAUG ) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of [...]
Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
25/10/2018
TOKYO and CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: [...]

Pages